SOUTH SAN FRANCISCO, Calif.,
Jan. 5, 2017 /PRNewswire/ -- VistaGen
Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage
biopharmaceutical company focused on developing new generation
therapies for depression and other central nervous system (CNS)
disorders, announced today that the Company will be presenting at
the 9th Annual Biotech Showcase™ conference. Shawn
Singh, Chief Executive Officer, will provide an overview of the
Company and AV-101, its orally available, new generation,
antidepressant prodrug candidate, on Tuesday, January 10, 2017, at 3:30 p.m. PST (6:30 p.m.
EST). The conference will be held in San Francisco from January 9th -11th.
A live audio webcast and replay of the presentation will be
available by accessing the IR Calendar in the Investors section of
VistaGen's website (www.vistagen.com). The replay of the webcast
will be available for 90 days, starting approximately two hours
after the presentation ends. Please connect to VistaGen's
website several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.
About AV-101
AV-101 (4-CI-KYN) is an orally
available CNS prodrug candidate, currently in Phase 2 development,
initially for the adjunctive treatment of major depressive disorder
(MDD) in patients with an inadequate response to standard
FDA-approved antidepressants. AV-101 also has broad potential
utility in several other CNS disorders, including chronic
neuropathic pain and epilepsy, as well as neurodegenerative
diseases, such as Parkinson's disease and Huntington's disease.
AV-101 is currently being evaluated in a Phase 2a monotherapy
study in MDD, a study being fully funded by the U.S. National
Institute of Mental Health (NIMH) and conducted by Dr.
Carlos Zarate Jr., Chief, Section on
the Neurobiology and Treatment of Mood Disorders and Chief of
Experimental Therapeutics and Pathophysiology Branch at the
NIMH.
VistaGen is preparing to advance AV-101 into a 280-patient, U.S.
multi-center, Phase 2b adjunctive treatment study in MDD in the
first half of 2017, with Dr. Maurizio
Fava of Harvard University as
Principal Investigator.
About VistaGen
VistaGen Therapeutics, Inc. (NASDAQ:
VTGN), is a clinical-stage biopharmaceutical company focused on
developing new generation therapies for depression and other
central nervous system (CNS) disorders. VistaGen's lead CNS
product candidate is AV-101, a new generation, orally available
prodrug in Phase 2 development in the U.S. for treatment of major
depressive disorder (MDD). AV-101 is currently being evaluated in a
Phase 2a monotherapy study in MDD, a study being fully funded by
the U.S. National Institute of Mental Health (NIMH) and
conducted by Dr. Carlos Zarate Jr.,
Chief, Section on the Neurobiology and Treatment of Mood Disorders
and Chief of Experimental Therapeutics and Pathophysiology Branch
at the NIMH. VistaGen is preparing to launch, in the first half of
2017, a 280-patient Phase 2b adjunctive treatment study of AV-101
in MDD patients with inadequate response to standard, FDA-approved
antidepressants. Dr. Maurizio Fava
of Harvard University will be the
Principal Investigator of the Phase 2b study. AV-101's mechanism of
action is fundamentally differentiated from all FDA-approved
antidepressants, and all FDA-approved atypical antipsychotics used
with them adjunctively to treat MDD, with potential to drive a
paradigm shift towards a new generation of safer and faster-acting
antidepressants.
VistaStem Therapeutics is VistaGen's wholly owned subsidiary
focused on applying human pluripotent stem cell technology to
discover, rescue, develop and commercialize proprietary new
chemical entities (NCEs), including small molecule NCEs with
regenerative potential, for CNS and other diseases, as well as
potential cellular therapies involving stem cell-derived blood,
cartilage and liver cells. In December
2016, VistaGen exclusively sublicensed to BlueRock
Therapeutics, a stem cell research company recently established by
Bayer AG and Versant Ventures, rights to certain proprietary
technologies relating to the production of cardiac stem cells for
the treatment of heart disease.
For more information, please visit www.vistagen.com and connect
with VistaGen on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
The statements in this
press release that are not historical facts may constitute
forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual
future results to differ materially from those expressed or implied
by such statements. Those risks and uncertainties include, but are
not limited to, risks related to the development and
commercialization of AV-101 and/or licensed and/or sublicensed
cardiac stem cell technology for cell therapy, drug discovery, drug
rescue or regenerative medicine, including the development and
commercialization activities described above. These and other risks
and uncertainties are identified and described in more detail in
VistaGen's filings with the Securities and Exchange Commission
(SEC). These filings are available on the SEC's website at
www.sec.gov. VistaGen undertakes no obligation to publicly update
or revise any forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vistagen-therapeutics-to-present-at-biotech-showcase-2017-300386364.html
SOURCE VistaGen Therapeutics, Inc.